Intelligence and Investigation Talent Moves (December 2020)

Ken Chan
3 min readDec 31, 2020

Yesterday, the COVID-19 vaccine developed by the University of Oxford and AstraZeneca was approved for use in the UK’s vaccination programme. Today, China’s State Food and Drug Administration also gave conditional approval to a vaccine developed by Sinopharm.

By the end of 2020, national regulatory authorities have approved six vaccines for public use. There are three categories of them: conventional inactivated vaccines, mRNA vaccines and viral vector vaccines.

Conventional inactivated vaccines: CoronaVac by Sinovac (left) BBIBP-CorV by Sinopharm (right)
mRNA vaccines: Tozinameran (a.k.a Comirnaty) by Pfizer-BioNTech (left) mRNA-1273 by Moderna (right)
Viral vector vaccines: Sputnik V by Russia’s Gamaleya Institute (left) AZD1222 by Oxford-AstraZeneca (right)

In the EU, Pfizer-BioNTech’s vaccine will be sold under the brand name “Comirnaty”. The meaning of “Comirnaty” is said to be a combination of the terms COVID-19, mRNA, community, and immunity. The name was developed by the naming agency Brand Institute.

For a pharma company, the vaccine brand name is an important intangible asset. Would there be any loophole in the brand protection strategy, such that the relevant domain name is left unregistered? Certainly no. We conducted a WHOIS search and found that:

Hope that 2021 will be a better year. Next, we continue to look at some of the personnel changes in the intelligence, investigation and consultancy industry. The information is obtained through our sources as well as research of LinkedIn, Glassdoor, corporate and news websites etc.

--

--